The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ENTX | +21.98% | +101.82% | +15.06% | -65% |
| S&P | +16.9% | +95.99% | +14.39% | +150% |
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.01M | -177.8% |
| Gross Margin | 0.00% | 0.0% |
| Market Cap | $86.36M | 31.0% |
| Market Cap / Employee | $4.11M | 18.6% |
| Employees | 21 | 0.0% |
| Net Income | -$2.66M | -23.8% |
| EBITDA | -$2.66M | -23.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $18.87M | 106.6% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.01M | -95.0% |
| Short Term Debt | $0.19M | 25.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -71.39% | 12.0% |
| Return On Invested Capital | -101.94% | -5.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.67M | -28.0% |
| Operating Free Cash Flow | -$1.65M | -25.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.09 | 12.00 | 8.17 | 4.45 | -39.62% |
| Price to Sales | 722.47 | 454.89 | 330.68 | 536.08 | -55.23% |
| Price to Tangible Book Value | 8.09 | 12.00 | 8.17 | 4.45 | -39.62% |
| Enterprise Value to EBITDA | -21.54 | -31.79 | -20.90 | -26.43 | -4.25% |
| Return on Equity | -144.7% | -103.3% | -71.5% | -82.2% | -19.26% |
| Total Debt | $0.31M | $0.27M | $0.22M | $0.20M | -39.22% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
